Pharmacokinetics in drug discovery

Journal of Pharmaceutical Sciences

Volumn 97, Issue 2, 2008, Pages 654-690

  Ruiz Garcia, Ana ^a   Bermejo, Marival ^b   Moss, Aaron ^c   Casabo, Vicente G ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Absorption; ADME; Bioequivalence; Biopharmaceutics classification system (BCS); Biophysical models; Computational ADME; Pharmacokinetic pharmacodynamic models; Population pharmacokinetics; Structure activity relatioship (SAR); Toxicology

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ARYL SULFOTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; LIPOSOME; OCTANOL; PEPTIDE TRANSPORTER 1; POTASSIUM CHANNEL HERG; WATER;

AMES TEST; ARTIFICIAL MEMBRANE; BIOEQUIVALENCE; BIOLOGICAL ACTIVITY; CELL CULTURE; CLONOGENIC ASSAY; COMET ASSAY; COMPUTER MODEL; CYTOTOXICITY; DNA MICROARRAY; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOXICITY; EQUILIBRIUM DIALYSIS; GENOMICS; GENOTOXICITY; HEART REPOLARIZATION; HIGH THROUGHPUT SCREENING; INTESTINE PERFUSION; LIVER CYTOSOL; LIVER MICROSOME; LIVER TOXICITY; MATHEMATICAL MODEL; MEMBRANE VESICLE; METABOLOMICS; MOLECULAR MODEL; NEPHROTOXICITY; PARTITION COEFFICIENT; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION; PROTEOMICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; ULTRAFILTRATION; X RAY CRYSTALLOGRAPHY;

EID: 39749120717     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21009     Document Type: Review

References (276)

1. 1991. Is there a need for more precise definitions of bioavailability? Conclusions of a consensus workshop, Munich, September 9, 1989;under the patronage of the F.I.P. Eur J Clin Pharmacol 40:123-126.
2. Hayes S, Dunne A, Smart T, Davis J. 2004. Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC). J Pharm Sci 93:571-581.
3. Uppoor VR. 2001. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J Control Release 72:127-132.
4. Lake OA, Olling M, Barends DM. 1999. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. Eur J Pharm Biopharm 48:13-19.
5. Malinowski HJ. 1997. The role of in vitro-in vivo correlations (IVIVC) to regulatory agencies. Adv Exp Med Biol 423:261-268.
6. Gillespie WR. 1997. Convolution-based approaches for in vivo-in vitro correlation modeling. Adv Exp Med Biol 423:53-65.
7. Elkoshi Z. 1999. Dissolution specifications based on release rates. J Pharm Sci 88:434-444.
8. Chen J, Ping QN, Guo JX, Chu XZ, Song MM. 2006. Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev Ind Pharm 32:719-726.
9. Lowis S, Lewis I, Elsworth A, Weston C, Doz F, Vassal G, Bellott R, Robert J, Pein F, Ablett S, Pinkerton R, Frappaz D. 2006. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br J Cancer 95:571-580.
10. Bedikian AY, Vardeleon A, Smith T, Campbell S, Namdari R. 2006. Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J Clin Pharmacol 46:727-737.
11. Mavroudis D, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V. 2002. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors. Oncology 62:216-222.
12. van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A. 2000. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. Anticancer Drugs 11:331-337.
13. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715.
14. Development TCftSoD. 2005. ed.
15. Fostel J. 2005. Predictive ADME-Tox London, UK, 27-28April2005. Expert Opin Drug Metab Toxicol 1:565-570.
16. van de Waterbeemd H, Gifford E. 2003. ADMET in silico modelling: Towards prediction paradise? Nat Rev Drug Discov 2:192-204.
17. O'Brien SE, de Groot MJ. 2005. Greater than the sum of its parts: Combining models for useful ADMET prediction. J Med Chem 48:1287-1291.
18. Kennedy T. 1997. Managing the drug discovery/development interface. Drug Discovery Today 2:436-444.
19. (CDER) USDoHaHSFaDACfDEaR. 2006. Guidance for Industry, Investigators and Reviewers. Exploratory IND studies
20. Kansy M, Senner F, Gubernator K. 1998. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 41:1007-1010.
21. (CDER) USDoHaHSFaDACfDEaR. 2003. Bioavailability and bioequivalence studies for orally administered drug products - General considerations.
22. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
23. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. 2002. Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res 19:921-925.
24. CDER/FDA. 1995. November 1995 Guidance for industry, Immediate Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes
25. Sun H. 2005. A naive bayes classifier for prediction of multidrug resistance reversal activity on the basis of atom typing. J Med Chem 48:4031-4039.
26. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
27. FDA Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification systemhttp://www.fda.gov/cder/index.htm. Accesed March 14th, 2004.
28. Klopman G, Zhu H. 2005. Recent methodologies for the estimation of n-octanol/water partition coefficients and their use in the prediction of membrane transport properties of drugs. Mini Rev Med Chem 5:127-133.
29. Yoshida F, Topliss JG. 2000. QSAR model for drug human oral bioavailability. J Med Chem 43:2575-2585.
30. Guttendorf R. 1996. The emerging role of A.D.M.E in optimizing drug discovery and design. Network Science.
31. Donato MT, Castell JV. 2003. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: Focus on in vitro studies. Clin Pharmacokinet 42:153-178.
32. Brandon EF, Raap CD, Meijerman I, Beijnen JH, Schellens JH. 2003. An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons. Toxicol Appl Pharmacol 189:233-246.
33. Bursi R, de Gooyer ME, Grootenhuis A, Jacobs PL, van der Louw J, Leysen D. 2001. (Q) SAR study on the metabolic stability of steroidal androgens. J Mol Graph Model 19:552-556, 607-608.
34. de Groot MJ. 2006. Designing better drugs: Predicting cytochrome P450 metabolism. Drug Discov Today 11:601-606.
35. Joukhadar C, Muller M. 2005. Microdialysis: Current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 44:895-913.
36. Eriksson MA, Gabrielsson J, Nilsson LB. 2005. Studies of drug binding to plasma proteins using a variant of equilibrium dialysis. J Pharm Biomed Anal 38:381-389.
37. Pacifici GM, Viani A. 1992. Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 23:449-468.
38. Muller L, Kikuchi Y, Probst G, Schechtman L, Shimada H, Sofuni T, Tweats D. 1999. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: Evolution, reasoning and impact. Mutat Res 436:195-225.
39. Ashby J. 1992. Use of short-term tests in determining the genotoxicity or nongenotoxicity of chemicals. IARC Sci Publ 116:135-164.
40. Sorsa M. EncyclopaediaofOccupationalHelathand Safety. GenotoxicChemicals.
41. Ames BN, McCann J, Yamasaki E. 1975. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 31:347-364.
42. Ames BN, McCann J, Yamasaki E. 1975. Proceedings: Carcinogens are mutagens: A simple test system. Mutat Res 33:27-28.
43. Kazius J, McGuire R, Bursi R. 2005. Derivation and validation of toxicophores for mutagenicity prediction. J Med Chem 48:312-320.
44. Singh NP, McCoy MT, Tice RR, Schneider EL. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191.
45. Singh NP, Danner DB, Tice RR, McCoy MT, Collins GD, Schneider EL. 1989. Abundant alkali-sensitive sites in DNA of human and mouse sperm. Exp Cell Res 184:461-470.
46. Ostling O, Johanson KJ. 1984. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem Biophys Res Commun 123:291-298.
47. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221.
48. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
49. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601.
50. Voigt W. 2005. Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110:39-48.
51. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
52. Cheung RY, Rauth AM, Ronaldson PT, Bendayan R, Wu XY. 2006. In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin. Eur J Pharm Biopharm 62:321-331.
53. Dal Negro G, Vandin L, Bonato M, Repeto P, Sciuscio D. 2006. A new experimental protocol as an alternative to the colony-forming unit-granulocyte/macrophage (CFU-GM) clonogenic assay to assess the haematotoxic potential of new drugs. Toxicol In Vitro 20:750-756.
54. Davila JC, Rodriguez RJ, Melchert RB, Acosta D. 1998. Predictive value of in vitro model systems in toxicology. Ann Rev Pharmacol Toxicol 38:63-96.
55. Korting HC, Herzinger T, Hartinger A, Kerscher M, Angerpointner T, Maibach HI. 1994. Discrimination of the irritancy potential of surfactants in vitro by two cytotoxicity assays using normal human keratinocytes, HaCaT cells, and 3T3 mouse fibroblasts: Correlation with in vivo data from a soap chamber assay. J Dermatol Sci 7:119.
56. Grant RL, Yao C, Gabaldon D, Acosta D. 1992. Evaluation of surfactant cytotoxicity potential by primary cultures of ocular tissues: I. Characterization of rabbit corneal epithelial cells and initial injury and delayed toxicity studies. Toxicology 76:153.
57. Korting HC, Schindler S, Hartinger A, Kerscher M, Angerpointner T, Maibach HI. 1994. MTT-assay and neutral red release (NRR)-assay: Relative role in the prediction of the irritancy potential of surfactants. Life Sci 55:533.
58. Xu JJ, Diaz D, O'Brien PJ. 2004. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 150:115-128.
59. Suter W. 2006. Predictive value of in vitro safety studies. Curr Opin Chem Biol 10:362-366.
60. Farkas D, Tannenbaum SR. 2005. In vitro methods to study chemically-induced hepatotoxicity: A literature review. Curr Drug Metab 6:111-125.
61. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K. 2006. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 54:116-129.
62. Pugsley MK, Curtis MJ. 2006. Safety pharmacology in focus: New methods developed in the light of the ICH S7B guidance document. J Pharmacol Toxicol Methods
63. Moss AJ, Zareba W, Kaufman ES, Gartman E, Peterson DR, Benhorin J, Towbin JA, Keating MT, Priori SG, Schwartz PJ, Vincent GM, Robinson JL, Andrews ML, Feng C, Hall WJ, Medina A, Zhang L, Wang Z. 2002. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 105:794-799.
64. Yoshida K, Niwa T. 2006. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels. J Chem Inf Model 46:1371-1378.
65. Stouch TR, Kenyon JR, Johnson SR, Chen XQ, Doweyko A, Li Y. 2003. In silico ADME/Tox: Why models fail. J Comput Aided Mol Des 17:83-92.
66. Rao S, Aoyama R, Schrag M, Trager WF, Rettie A, Jones JP. 2000. A refined 3-dimensional QSAR of cytochrome P450 2 C9: Computational predictions of drug interactions. J Med Chem 43:2789-2796.
67. Medvedev AE, Veselovsky AV, Shvedov VI, Tikhonova OV, Moskvitina TA, Fedotova OA, Axenova LN, Kamyshanskaya NS, Kirkel AZ, Ivanov AS. 1998. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis. J Chem Inf Comput Sci 38:1137-1144.
68. Swaan PW, Szoka FC Jr, Oie S. 1997. Molecular modeling of the intestinal bile acid carrier: A comparative molecular field analysis study. J Comput Aided Mol Des 11:581-588.
69. Cianchetta G, Li Y, Kang J, Rampe D, Fravolini A, Cruciani G, Vaz RJ. 2005. Predictive models for hERG potassium channel blockers. Bioorg Med Chem Lett 15:3637-3642.
70. Swaan PW, Koops BC, Moret EE, Tukker JJ. 1998. Mapping the binding site of the small intestinal peptide carrier (PepT1) using comparative molecular field analysis. Receptors Channels 6:189-200.
71. Pajeva I, Wiese M. 1998. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study. J Med Chem 41:1815-1826.
72. Singh SK, Dessalew N, Bharatam PV. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors. Eur J Med Chem 41:1310-1319.
73. López de Briñas ELJ, Centeno NB, Segura J, González-Merino ML, de la Torre R, Sanz F. 2000. Pharmacophore development for the interaction of cytochrome P450 1A2 with its substrates and inhibitors edition. New York: Kluwer Academic/Plenum Publishers. pp 141-146.
74. de Groot MJ, Alex AA, Jones BC. 2002. Development of a combined protein and pharmacophore model for cytochrome P450 2 C9. J Med Chem 45:1983-1993.
75. Boyer S, Zamora I. 2002. New methods in predictive metabolism. J Comput Aided Mol Des 16:403-413.
76. Snyder Richard, Sangar Rajesh, Wang Jibo, Ekins Sean. 2002. Three-dimensional quantitative structure activity relationship for Cyp2d6 substrates. Quant Structure-Activity Relationship 21:357-368.
77. Egnell AC, Houston JB, Boyer CS. 2005. Predictive models of CYP3A4 heteroactivation: In vitro-in vivo scaling and pharmacophore modeling. J Pharmacol Exp Ther 312:926-937.
78. Ekins S, Stresser DM, Williams JA. 2003. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 24:161-166.
79. Tanaka T, Okuda T, Yamamoto Y. 2004. Characterization of the CYP3A4 active site by homology modeling. Chem Pharm Bull (Tokyo) 52:830-835.
80. Ekins S, Ring BJ, Bravi G, Wikel JH, Wrighton SA. 2000. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millenium, edition. La Jolla, CA: International University Line. pp 269-299.
81. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA. 2002. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61:974-981.
82. Penzotti JE, Lamb ML, Evensen E, Grootenhuis PD. 2002. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 45:1737-1740.
83. Rao GS, Ramachandran MV, Bajaj JS. 2006. In silico structure-based design of a potent and selective small peptide inhibitor of protein tyrosine phosphatase 1B, a novel therapeutic target for obesity and type 2 diabetes mellitus: A computer modeling approach. J Biomol Struct Dyn 23:377-384.
84. Yoshitani N, Satou K, Saito K, Suzuki S, Hatanaka H, Seki M, Shinozaki K, Hirota H, Yokoyama S. 2005. A structure-based strategy for discovery of small ligands binding to functionally unknown proteins: Combination of in silico screening and surface plasmon resonance measurements. Proteomics 5:1472-1480.
85. Matyas G, Arnold E, Carrel T, Baumgartner D, Boileau C, Berger W, Steinmann B. 2006. Identification and in silico analyses of novel TGFBR1 and TGFBR2 mutations in Marfan syndrome-related disorders. Hum Mutat 27:760-769.
86. Miguet L, Zhang Z, Barbier M, Grigorov MG. 2006. Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11beta HSD1) in a structure-based identification of inhibitors. J Comput Aided Mol Des 20:67-81.
87. Yu J, Paine MJ, Marechal JD, Kemp CA, Ward CJ, Brown S, Sutcliffe MJ, Roberts GC, Rankin EM, Wolf CR. 2006. In silico prediction of drug binding to CYP2 D6: Identification of a new metabolite of metoclopramide. Drug Metab Dispos 34:1386-1392.
88. Prosser DE, Guo Y, Jia Z, Jones G. 2006. Structural motif-based homology modeling of CYP27A1 and site-directed mutational analyses affecting vitamin D hydroxylation. Biophys J 90:3389-3409.
89. Wang Q, Halpert JR. 2002. Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab Dispos 30:86-95.
90. Lewis DF, Ito Y, Goldfarb PS. 2006. Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily. Curr Drug Metab 7:589-598.
91. Lee H, Yeom H, Kim YG, Yoon CN, Jin C, Choi JS, Kim BR, Kim DH. 1998. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem Pharmacol 55:1369-1375.
92. Altomare C, Cellamare S, Summo L, Catto M, Carotti A, Thull U, Carrupt PA, Testa B, Stoeckli-Evans H. 1998. Inhibition of monoamine oxidase-B by condensed pyridazines and pyrimidines: Effects of lipophilicity and structure-activity relationships. J Med Chem 41:3812-3820.
93. Campbell NR, Van Loon JA, Sundaram RS, Ames MM, Hansch C, Weinshilboum R. 1987. Human and rat liver phenol sulfotransferase: Structure-activity relationships for phenolic substrates. Mol Pharmacol 32:813-819.
94. Mercier C, Fabart V, Sobel Y, Dubois JE. 1991. Modeling alcohol metabolism with the DARC/CALPHI system. J Med Chem 34:934-942.
95. Mercier CSY, Dubois JE. 1992. DARC/PELCO method: A topological tool for QSAR search and its reliable predictive capability. Philadelphia: Gordon and Breach. pp 199-257.
96. Hansch C, Leo A, Mekapati SB, Kurup A. 2004. QSAR and ADME. Bioorg Med Chem 12:3391-3400.
97. Karelson M, Lobanov VS, Katritzky AR. 1996. Quantum-chemical descriptors in QSAR/QSPR studies. Chem Rev 96:1027-1044.
98. Katritzky AR, Kuanar M, Fara DC, Karelson M, Acree WE Jr. 2004. QSPR treatment of rat blood-air, saline:air and olive oil:air partition coefficients using theoretical molecular descriptors. Bioorg Med Chem 12:4735-4748.
99. Katritzky AR, Petrukhin R, Jain R, Karelson M. 2001. QSPR analysis of flash points. J Chem Inf Comput Sci 41:1521-1530.
100. Bermejo M, Merino V, Garrigues TM, Pla Delfina JM, Mulet A, Vizet P, Trouiller G, Mercier C. 1999. Validation of a biophysical drug absorption model by the PATQSAR system. J Pharm Sci 88:398-405.
101. Tantishaiyakul V. 2005. Prediction of the aqueous solubility of benzylamine salts using QSPR model. J Pharm Biomed Anal 37:411-415.
102. Wedge D, Ingram D, McLean D, Mingham C, Bandar Z. 2006. On global-local artificial neural networks for function approximation. IEEE Trans Neural Netw 17:942-952.
103. Engkvist O, Wrede P. 2002. High-throughput, in silico prediction of aqueous solubility based on one- and two-dimensional descriptors. J Chem Inf Comput Sci 42:1247-1249.
104. Li H, Yap CW, Xue Y, Li ZR, Ung CY, Han LY, Han YZ, Chen YZ. 2005. Statistical learning approach for predicting specific pharmacodynamic, pharmacokinetic, or toxicological properties of pharmaceutical agents. Drug Develop Res 66:245-259.
105. Sutton SC, Hu M. 2006. An automated process for building reliable and optimal in vitro/in vivo correlation models based on Monte Carlo simulations. Aaps J 8:E307-313.
106. Kortejarvi H, Malkki J, Marvola M, Urtti A, Yliperttula M, Pajunen P. 2006. Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series. J Pharm Sci 95:1595-1605.
107. Dahl SG, Sylte I. 2006. From genomics to drug targets. J Psychopharmacol 20:95-99.
108. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ. 2006. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924-1931.
109. He YD. 2006. Genomic approach to biomarker identification and its recent applications. Cancer Biomark 2:103-133.
110. Anderson NL, Anderson NG. 1998. Proteome and proteomics: New technologies, new concepts, and new words. Electrophoresis 19:1853-1861.
111. Blackstock WP, Weir MP. 1999. Proteomics: Quantitative and physical mapping of cellular proteins. Trends Biotechnol 17:121-127.
112. Kennedy S. 2002. The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers 7:269-290.
113. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. 2004. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 4:3276-3287.
114. Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, George A, Katenhusen R, Buchowiecka A, Arciero C, Brzeski H, Hooke J, Shriver C. 2003. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 3:1863-1873.
115. O'Driscoll L, Clynes M. 2006. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets 6:365-384.
116. Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J. 2006. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9:293-348.
117. Diamond DL, Proll SC, Jacobs JM, Chan EY, Camp DG 2nd, Smith RD, Katze MG. 2006. HepatoProteomics: Applying proteomic technologies to the study of liver function and disease. Hepatology 44:299-308.
118. Williams RE, Lenz EM, Lowden JS, Rantalainen M, Wilson ID. 2005. The metabonomics of aging and development in the rat: An investigation into the effect of age on the profile of endogenous metabolites in the urine of male rats using (1)H NMR and HPLC-TOF MS. Mol Biosyst 1:166-175.
119. Robertson DG, Reily MD, Baker JD. 2005. Metabonomics in preclinical drug development. Expert Opin Drug Metab Toxicol 1:363-376.
120. Craig A, Sidaway J, Holmes E, Orton T, Jackson D, Rowlinson R, Nickson J, Tonge R, Wilson I, Nicholson J. 2006. Systems toxicology: Integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J Proteome Res 5:1586-1601.
121. Pedraza A, Sicilia MD, Rubio S, Perez-Bendito D. 2006. Pharmaceutical quality control of acid and neutral drugs based on competitive self-assembly in amphiphilic systems. Analyst 131:81-89.
122. Bamiro OA, Odeniyi MA, Idowu OB, Jaiyeoba KT. 2004. Physicochemical equivalence of chloroquine phosphate tablets. Afr J Med Med Sci 33:371-375.
123. Garcia CV, Paim CS, Steppe M, Schapoval EE. 2006. Development and validation of a dissolution test for rabeprazole sodium in coated tablets. J Pharm Biomed Anal 41:833-837.
124. Merino V, Freixas J, del Val Bermejo M, Garrigues TM, Moreno J, Pla-Delfina JM. 1995. Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones. J Pharm Sci 84:777-782.
125. Bermejo M, Avdeef A, Ruiz A, Nalda R, Ruell JA, Tsinman O, Gonzalez I, Fernandez C, Sanchez G, Garrigues TM, Merino V. 2004. PAMPA-a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci 21:429-441.
126. van De Waterbeemd H, Smith DA, Beaumont K, Walker DK. 2001. Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem 44:1313-1333.
127. Edward HK. 2001. High throughput physicochemical profiling for drug discovery. J Pharma Sci 90:1838-1858.
128. Balon K, Riebesehl BU, Muller BW. 1999. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm Res 16:882-888.
129. Avdeef A, Box KJ, Comer JE, Hibbert C, Tam KY. 1998. pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm Res 15:209-215.
130. Stewart BH, Chan OH, Jezyk N, Fleisher D. 1997. Discrimination between drug candidates using models for evaluation of intestinal absorption. Adv Drug Delivery Rev 23:27-45.
131. Stevens BR, Ross HJ, Wright EM. 1982. Multiple transport pathways for neutral amino acids in rabbit jejunal brush border vesicles. J Membr Biol 66:213-225.
132. Dudeja PK, Harig JM, Wali RK, Knaup SM, Ramaswamy K, Brasitus TA. 1991. Differential modulation of human small intestinal brush-border membrane hemileaflet fluidity affects leucine aminopeptidase activity and transport of D-glucose and L-glutamate. Arch Biochem Biophys 284: 338-345.
133. Yao HM, Chiou WL. 2006. The complexity of intestinal absorption and exsorption of digoxin in rats. Int J Pharm 322:79-86.
134. Harrison DD, Webster HL. 1971. Proximal to distal variations in enzymes of the rat intestine. Biochim Biophys Acta 244:432-436.
135. Bai JP. 1993. Distribution of brush-border membrane peptidases along the rabbit intestine: Implication for oral delivery of peptide drugs. Life Sci 52:941-947.
136. Tobey N, Heizer W, Yeh R, Huang TI, Hoffner C. 1985. Human intestinal brush border peptidases. Gastroenterology 88:913-926.
137. TenHoor CN, Stewart BH. 1995. Reconversion of fosphenytoin in the presence of intestinal alkaline phosphatase. Pharm Res 12:1806-1809.
138. Stewart BH, Chan OH, Lu RH, Reyner EL, Schmid HL, Hamilton HW, Steinbaugh BA, Taylor MD. 1995. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: Relationship to absorption in humans. Pharm Res 12:693-699.
139. Leppert PS, Fix JA. 1994. Use of everted intestinal rings for in vitro examination of oral absorption potential. J Pharm Sci 83:976-981.
140. Artursson P, Ungell AL, Lofroth JE. 1993. Selective paracellular permeability in two models of intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 10:1123-1129.
141. Wohnsland F, Faller B. 2001. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44:923-930.
142. Matsson P, Bergstrom CA, Nagahara N, Tavelin S, Norinder U, Artursson P. 2005. Exploring the role of different drug transport routes in permeability screening. J Med Chem 48:604-613.
143. Ruell JA, Tsinman KL, Avdeef A. 2003. PAMPA - a drug absorption in vitro model. 5. Unstirred water layer in iso-pH mapping assays and pKa (flux) - optimized design (pOD-PAMPA). Eur J Pharm Sci 20:393-402.
144. Sugano K, Hamada H, Machida M, Ushio H, Saitoh K, Terada K. 2001. Optimized conditions of bio-mimetic artificial membrane permeation assay. Int J Pharm 228:181-188.
145. Matsumoto S, Saito H, Inui K. 1994. Transcellular transport of oral cephalosporins in human intestinal epithelial cells, Caco-2: Interaction with dipeptide transport systems in apical and basolateral membranes. J Pharmacol Exp Ther 270:498-504.
146. Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, Jenkins IL, Duckworth DC, Sportsman JR, Mackensen D, Rosteck PR Jr, et al. 1994. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science 264:430-433.
147. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. 1993. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 268:14991-14997.
148. Phung-Ba V, Warnery A, Scherman D, Wils P. 1995. Interaction of pristinamycin IA with P-glycoprotein in human intestinal epithelial cells. Eur J Pharmacol 288:187-192.
149. Dean M, Allikmets R. 1995. Evolution of ATP-binding cassette transporter genes. Curr Opin Genet Dev 5:779-785.
150. Higgins CF. 1992. ABC transporters: From microorganisms to man. Annu Rev Cell Biol 8:67-113.
151. Dean M, Rzhetsky A, Allikmets R. 2001. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11:1156-1166.
152. Cho MJ, Thompson DP, Cramer CT, Vidmar TJ, Scieszka JF. 1989. The Madin Darby canine kidney (MDCK) epithelial cell monolayer as a model cellular transport barrier. Pharm Res 6:71-77.
153. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR. 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88:28-33.
154. Li H, Chung SJ, Shim CK. 2002. Characterization of the transport of uracil across Caco-2 and LLC-PK1 cell monolayers. Pharm Res 19:1495-1501.
155. Pidgeon C, Ong S, Liu H, Qiu X, Pidgeon M, Dantzig AH, Munroe J, Hornback WJ, Kasher JS, Glunz L, et al. 1995. IAM chromatography: An in vitro screen for predicting drug membrane permeability. J Med Chem 38:590-594.
156. Ong S, Liu H, Pidgeon C. 1996. Immobilized-artificial-membrane chromatography: Measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatogr A 728:113-128.
157. Ong S, Liu H, Qiu X, Bhat G, Pidgeon C. 1995. Membrane partition coefficients chromatographically measured using immobilized artificial membrane surfaces. Anal Chem 67:755-762.
158. Pidgeon C, Cai SJ, Bernal C. 1996. Mobile phase effects on membrane protein elution during immobilized artificial membrane chromatography. J Chromatogr A 721:213-230.
159. Lazaro E, Rafols C, Abraham MH, Roses M. 2006. Chromatographic estimation of drug disposition properties by means of immobilized artificial membranes (IAM) and C18 columns. J Med Chem 49:4861-4870.
160. Rodriguez-Ibanez M, Sanchez-Castano G, Montalar-Montero M, Garrigues TM, Bermejo M, Merino V. 2006. Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin. Int J Pharm 307:33-41.
161. Fernandez-Teruel C, Gonzalez-Alvarez I, Casabo VG, Ruiz-Garcia A, Bermejo M. 2005. Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells. J Drug Target 13:199-212.
162. Ferrando R, Garrigues TM, Bermejo MV, Martin-Algarra R, Merino V, Polache A. 1999. Effects of ethanol on intestinal absorption of drugs: In situ studies with ciprofloxacin analogs in acute and chronic alcohol-fed rats. Alcohol Clin Exp Res 23:1403-1408.
163. Doluisio JT, Billups NF, Dittert LW, Sugita ET, Swintosky JV. 1969. Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. J Pharm Sci 58:1196-1200.
164. Patel N, Forbes B, Eskola S, Murray J. 2006. Use of simulated intestinal fluids with Caco-2 cells and rat ileum. Drug Dev Ind Pharm 32:151-161.
165. Carr G, Haslam IS, Simmons NL. 2006. Voltage dependence of transepithelial guanidine permeation across Caco-2 epithelia allows determination of the paracellular flux component. Pharm Res 23:540-548.
166. Hocht C, Opezzo JA, Taira CA. 2004. Microdialysis in drug discovery. Curr Drug Discov Technol 1:269-285.
167. Brunner M, Langer O. 2006. Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. Aaps J 8:E263-E271.
168. Islinger F, Dehghanyar P, Sauermann R, Burger C, Kloft C, Muller M, Joukhadar C. 2006. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents 27:108-112.
169. Barrail A, Le Tiec C, Paci-Bonaventure S, Furlan V, Vincent I, Taburet AM. 2006. Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration. Ther Drug Monit 28:89-94.
170. Olsen H, Andersen A, Nordbo A, Kongsgaard UE, Bormer OP. 2004. Pharmaceutical-grade albumin: Impaired drug-binding capacity in vitro. BMC Clin Pharmacol 4:4.
171. Fung EN, Chen YH, Lau YY. 2003. Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 795:187-194.
172. Lin JH, Cocchetto DM, Duggan DE. 1987. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 12:402-432.
173. Taavitsainen P, Kiukaanniemi K, Pelkonen O. 2000. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 56:135-140.
174. Bhoopathy S, Xin B, Unger SE, Karnes HT. 2005. A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes. J Pharm Biomed Anal 37:739-749.
175. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O. 2005. Multiple P450 substrates in a single run: Rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 24:123-132.
176. Brill SS, Furimsky AM, Ho MN, Furniss MJ, Li Y, Green AG, Bradford WW, Green CE, Kapetanovic IM, Iyer LV. 2006. Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms. J Pharm Pharmacol 58:469-479.
177. Galetin A, Houston JB. 2006. Intestinal and hepatic metabolic activity of five cytochrome p450 enzymes: Impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220-1229.
178. Govoni M, Casagrande S, Maucci R, Chiroli V, Tocchetti P. 2006. In vitro metabolism of (nitrooxy)butyl ester nitric oxide-releasing compounds: Comparison with glyceryl trinitrate. J Pharmacol Exp Ther 317:752-761.
179. Shimada H, Miura K, Imamura Y. 2006. Characteristics and inhibition by flavonoids of 20alpha-hydroxysteroid dehydrogenase activity in mouse tissues. Life Sci 78:2931-2936.
180. Wu D, George TG, Hurh E, Werbovetz KA, Dalton JT. 2006. Pre-systemic metabolism prevents in vivo antikinetoplastid activity of N1, N4-substituted 3,5-dinitro sulfanilamide, GB-II-150. Life Sci 79:1081-1093.
181. Brandon EF, Sparidans RW, Guijt KJ, Lowenthal S, Meijerman I, Beijnen JH, Schellens JH. 2006. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anticancer drug. Invest New Drugs 24:3-14.
182. Maron DM, Ames BN. 1983. Revised methods for the Salmonella mutagenicity test. Mutat Res 113:173-215.
183. Roy P, Yu LJ, Crespi CL, Waxman DJ. 1999. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655-666.
184. Harrigan JA, McGarrigle BP, Sutter TR, Olson JR. 2006. Tissue specific induction of cytochrome P450 (CYP) 1A1 and 1B1 in rat liver and lung following in vitro (tissue slice) and in vivo exposure to benzo(a)pyrene. Toxicol In Vitro 20:426-438.
185. Bordelon NR, Chhabra R, Bucher JR. 2005. A review of evidence from short-term studies leading to the prediction that diazoaminobenzene (1,3-diphenyltriazine) is a carcinogen. J Appl Toxicol 25:514-521.
186. Persson KP, Ekehed S, Otter C, Lutz ES, McPheat J, Masimirembwa CM, Andersson TB. 2006. Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans. Pharm Res 23:56-69.
187. Walle T, Otake Y, Galijatovic A, Ritter JK, Walle UK. 2000. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line he p G2. Drug Metab Dispos 28:1077-1082.
188. O'Brien NM, Woods JA, Aherne SA, O'Callaghan YC. 2000. Cytotoxicity, genotoxicity and oxidative reactions in cell-culture models: Modulatory effects of phytochemicals. Biochem Soc Trans 28:22-26.
189. O'Brien T, Babcock G, Cornelius J, Dingeldein M, Talaska G, Warshawsky D, Mitchell K. 2000. A comparison of apoptosis and necrosis induced by hepatotoxins in HepG2 cells. Toxicol Appl Pharmacol 164:280-290.
190. O'Leary KA, Day AJ, Needs PW, Mellon FA, O'Brien NM, Williamson G. 2003. Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: The role of human beta-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 65:479-491.
191. Tan YL, Goh D, Ong ES. 2006. Investigation of differentially expressed proteins due to the inhibitory effects of berberine in human liver cancer cell line HepG2. Mol Biosyst 2:250-258.
192. Takahashi S, Takahashi T, Mizobuchi S, Matsumi M, Yokoyama M, Morita K, Miyazaki M, Namba M, Akagi R, Sassa S. 2003. CYP2E1 overexpression up-regulates both non-specific delta-aminolevulinate synthase and heme oxygenase-1 in the human hepatoma cell line HLE/2 E1. Int J Mol Med 11:57-62.
193. Takahashi S, Takahashi T, Mizobuchi S, Matsumi M, Morita K, Miyazaki M, Namba M, Akagi R, Hirakawa M. 2002. Increased cytotoxicity of carbon tetrachloride in a human hepatoma cell line overexpressing cytochrome P450 2 E1. J Int Med Res 30:400-405.
194. Hibasami H, Iwase H, Yoshioka K, Takahashi H. 2006. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int J Mol Med 17:215-219.
195. Gomez-Lechon MJ, Donato T, Jover R, Rodriguez C, Ponsoda X, Glaise D, Castell JV, Guguen-Guillouzo C. 2001. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur J Biochem 268:1448-1459.
196. Fabre N, Arrivet E, Trancard J, Bichet N, Roome NO, Prenez A, Vericat JA. 2003. A new hepatoma cell line for toxicity testing at repeated doses. Cell Biol Toxicol 19:71-82.
197. Paganelli G, Magnani P, Zito F, Lucignani G, Sudati F, Truci G, Motti E, Terreni M, Pollo B, Giovanelli M, et al. 1994. Pre-targeted immunodetection in glioma patients: Tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med 21:314-321.
198. O'Connor JE, Martinez A, Castell JV, Gomez-Lechon MJ. 2005. Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research. Cytometry A 63:48-58.
199. Pham TN, Marion M, Denizeau F, Jumarie C. 2006. Cadmium-induced apoptosis in rat hepatocytes does not necessarily involve caspase-dependent pathways. Toxicol In Vitro
200. Kane BJ, Zinner MJ, Yarmush ML, Toner M. 2006. Liver-specific functional studies in a microfluidic array of primary Mammalian hepatocytes. Anal Chem 78:4291-4298.
201. Yamazaki H, Oda Y, Funae Y, Imaoka S, Inui Y, Guengerich FP, Shimada T. 1992. Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis 13:979-985.
202. Elaut G, Henkens T, Papeleu P, Snykers S, Vinken M, Vanhaecke T, Rogiers V. 2006. Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr Drug Metab 7:629-660.
203. Nishimura M, Yokoi T, Tateno C, Kataoka M, Takahashi E, Horie T, Yoshizato K, Naito S. 2005. Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab Pharmacokinet 20:121-126.
204. Tomera JF, Skipper PL, Wishnok JS, Tannenbaum SR, Brunengraber H. 1984. Inhibition of N-nitrosodimethylamine metabolism by ethanol and other inhibitors in the isolated perfused rat liver. Carcinogenesis 5:113-116.
205. Strubelt O, Deters M, Pentz R, Siegers CP, Younes M. 1999. The toxic and metabolic effects of 23 aliphatic alcohols in the isolated perfused rat liver. Toxicol Sci 49:133-142.
206. Deters M, Strubelt O, Younes M. 1997. Reevaluation of cyclosporine induced hepatotoxicity in the isolated perfused rat liver. Toxicology 123:197-206.
207. Wu WN, McKown LA, Yorgey KA, Pritchard JF. 1999. In vitro metabolic products of RWJ-34130, an antiarrythmic agent, in rat liver preparations. J Pharm Biomed Anal 20:687-695.
208. Gawronska-Szklarz B, Musial HD, Loniewski I, Paprota B, Drozdzik M. 2006. Lidocaine metabolism in isolated perfused liver from streptozotocin-induced diabetic rats. J Pharm Pharmacol 58:1073-1077.
209. Knudsen H. 2004. Guide to Analysis of DNA Microarray Data, edition. New York: John Wiley and Sons Inc.
210. Schulze A, Downward J. 2001. Navigating gene expression using microarrays [mdash] a technology review. Nat Cell Biol 3:E190-E195.
211. Ejiri N, Katayama K, Kiyosawa N, Baba Y, Doi K. 2005. Microarray analysis on CYPs expression in pregnant rats after treatment with pregnenolone-16alpha- carbonitrile and phenobarbital. Exp Mol Pathol 78:71-77.
212. Ejiri N, Katayama K, Kiyosawa N, Baba Y, Doi K. 2005. Microarray analysis on Phase II drug metabolizing enzymes expression in pregnant rats after treatment with pregnenolone-16alpha-carbonitrile or phenobarbital. Exp Mol Pathol 79:272-277.
213. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart DJ, Morris MS, Fodor SP. 1996. Accessing genetic information with high-density DNA arrays. Science 274:610-614.
214. Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J, Woolley DE, Davis RW. 1997. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci U S A 94: 2150-2155.
215. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. 1997. Gene expression profiles in normal and cancer cells. Science 276:1268-1272.
216. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, Stoughton R, Burchard J, Slade D, Dai H, Bassett DE Jr, Hartwell LH, Brown PO, Friend SH. 1998. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature medicine 4:1293-1301.
217. Spellman PT, Sherlock G, Zhang MQ, Iyer VR, Anders K, Eisen MB, Brown PO, Botstein D, Futcher B. 1998. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol Biol Cell 9:3273-3297.
218. Holstege FC, Jennings EG, Wyrick JJ, Lee TI, Hengartner CJ, Green MR, Golub TR, Lander ES, Young RA. 1998. Dissecting the regulatory circuitry of a eukaryotic genome. Cell 95:717-728.
219. Roberts CJ, Nelson B, Marton MJ, Stoughton R, Meyer MR, Bennett HA, He YD, Dai H, Walker WL, Hughes TR, Tyers M, Boone C, Friend SH. 2000. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles. Science 287:873-880.
220. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, Stepaniants SB, Shoemaker DD, Gachotte D, Chakraburtty K, Simon J, Bard M, Friend SH. 2000. Functional discovery via a compendium of expression profiles. Cell 102:109-126.
221. Shoemaker DD, Schadt EE, Armour CD, He YD, Garrett-Engele P, McDonagh PD, Loerch PM, Leonardson A, Lum PY, Cavet G, Wu LF, Altschuler SJ, Edwards S, King J, Tsang JS, Schimmack G, Schelter JM, Koch J, Ziman M, Marton MJ, Li B, Cundiff P, Ward T, Castle J, Krolewski M, Meyer MR, Mao M, Burchard J, Kidd MJ, Dai H, Phillips JW, Linsley PS, Stoughton R, Scherer S, Boguski MS. 2001. Experimental annotation of the human genome using microarray technology. Nature 409:922-927.
222. Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG. 2001. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. Toxicol Letters 120:359-368.
223. Hamadeh HK, Bushel PR, Jayadev S, DiSorbo O, Bennett L, Li L, Tennant R, Stoll R, Barrett JC, Paules RS, Blanchard K, Afshari CA. 2002. Prediction of compound signature using high density gene expression profiling. Toxicol Sci 67:232-240.
224. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511.
225. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. 1999. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286:531-537.
226. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752.
227. Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS. 2001. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Med 7:673-679.
228. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 347:1999-2009.
229. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. 2002. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442.
230. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, van de Vijver MJ. 2005. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102: 3738-3743.
231. Amundson SA, Bittner M, Meltzer P, Trent J, Fornace AJ Jr. 2001. Induction of gene expression as a monitor of exposure to ionizing radiation. Radiat Res 156:657-661.
232. Curto EV, Lambert GW, Davis RL, Wilborn TW, Dooley TP. 2002. Biomarkers of human skin cells identified using DermArray DNA arrays and new bioinformatics methods. Biochem Biophys Res Commun 291:1052-1064.
233. Mao M, Biery MC, Kobayashi SV, Ward T, Schimmack G, Burchard J, Schelter JM, Dai H, He YD, Linsley PS. 2004. T lymphocyte activation gene identification by coregulated expression on DNA microarrays. Genomics 83:989-999.
234. Sun L, Luo C, Long J, Wei D, Liu J. 2006. Acrolein is a mitochondrial toxin: Effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Mitochondrion 6:136-142.
235. Bajt ML, Cover C, Lemasters JJ, Jaeschke H. 2006. Nuclear translocation of endonuclease g and apoptosis-inducing factor during acetaminophen-induced liver cell injury. Toxicol Sci 94:217-225.
236. Safiulina D, Peet N, Seppet E, Zharkovsky A, Kaasik A. 2006. Dehydroepiandrosterone inhibits complex I of the mitochondrial respiratory chain and is neurotoxic in vitro and in vivo at high concentrations. Toxicol Sci 93:348-356.
237. Teng S, Ma L, Dong Y, Lin C, Ye J, Bahring R, Vardanyan V, Yang Y, Lin Z, Pongs O, Hui R. 2004. Clinical and electrophysiological characterization of a novel mutation R863X in HERG C-terminus associated with long QT syndrome. J Mol Med 82:189-196.
238. Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathofer S, Thomas D, Weretka S, Peth S, Kreye VA, Schoels W, Katus HA, Kiehn J, Karle CA. 2003. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol 368:404-414.
239. Shioda T. 2004. Application of DNA microarray to toxicological research. J Environ Pathol Toxicol Oncol 23:13-31.
240. Lettieri T. 2006. Recent applications of DNA microarray technology to toxicology and ecotoxicology. Environ Health Perspect 114:4-9.
241. DiStefano JJ 3rd. 1982. Noncompartmental vs. compartmental analysis: Some bases for choice. Am J Physiol 243:R1-R6.
242. Nestorov I. 2003. Whole body pharmacokinetic models. Clin Pharmacokinet 42:883-908.
243. (CBER). USDoHaHSFaDACfDEaRCcfBEaR. 1999. Guidance for industry. Population Pharmacokinet
244. Aarons L. 1991. Population pharmacokinetics: Theory and practice. Br J Clin Pharmacol 32:669-670.
245. Bretschneider B, Brandsch M, Neubert R. 1999. Intestinal transport of beta-lactam antibiotics: Analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res 16:55-61.
246. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. 1998. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 6:317-324.
247. Clark DE. 1999. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 88:807-814.
248. Smialowski P, Martin-Galiano AJ, Mikolajka A, Girschick T, Holak TA, Frishman D. 2006. Protein solubility: Sequence based prediction and experimental verification. Bioinformatics Dec. 6 [Epub ahead of print].
249. Sanchez-Castano G, Ruiz-Garcia A, Banon N, Bermejo M, Merino V, Freixas J, Garriguesx TM, Pla-Delfina JM. 2000. Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or in vitro partition coefficients: 6-fluoroquinolones. J Pharm Sci 89:1395-1403.
250. Amidon GL, Sinko PJ, Fleisher D. 1988. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm Res 5:651-654.
251. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH. 2000. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44:251-272.
252. Balimane PV, Chong S. 2005. Cell culture-based models for intestinal permeability: A critique. Drug Discov Today 10:335-343.
253. Wei H, Lobenberg R. 2006. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur J Pharm Sci 29:45-52.
254. Sunesen VH, Pedersen BL, Kristensen HG, Mullertz A. 2005. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci 24:305-313.
255. Parojcic J, Ethuric Z, Jovanovic M, Ibric S, Jovanovic D. 2004. Influence of dissolution media composition on drug release and in-vitro/in-vivo correlation for paracetamol matrix tablets prepared with novel carbomer polymers. J Pharm Pharmacol 56:735-741.
256. Artursson P. 1991. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carrier Syst 8:305-330.
257. Rubas W, Cromwell ME, Shahrokh Z, Villagran J, Nguyen TN, Wellton M, Nguyen TH, Mrsny RJ. 1996. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci 85:165-169.
258. Artursson P, Palm K, Luthman K. 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43.
259. Adachi Y, Suzuki H, Sugiyama Y. 2003. Quantitative evaluation of the function of small intestinal P-glycoprotein: Comparative studies between in situ and in vitro. Pharm Res 20:1163-1169.
260. Tavelin S, Milovic V, Ocklind G, Olsson S, Artursson P. 1999. A conditionally immortalized epithelial cell line for studies of intestinal drug transport. J Pharmacol Exp Ther 290:1212-1221.
261. Tavelin S, Taipalensuu J, Hallbook F, Vellonen KS, Moore V, Artursson P. 2003. An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: Characterization of transport routes. Pharm Res 20:373-381.
262. Nagahara N, Tavelin S, Artursson P. 2004. Contribution of the paracellular route to the pH-dependent epithelial permeability to cationic drugs. J Pharm Sci 93:2972-2984.
263. Gonzalez-Alvarez I, Fernandez-Teruel C, Garrigues TM, Casabo VG, Ruiz-Garcia A, Bermejo M. 2005. Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NON-MEM. Xenobiotica 35:1067-1088.
264. Ruiz-Garcia A, Lin H, Pla-Delfina JM, Hu M. 2002. Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. J Pharm Sci 91:2511-2519.
265. Keely S, Rullay A, Wilson C, Carmichael A, Carrington S, Corfield A, Haddleton DM, Brayden DJ. 2005. In vitro and ex vivo intestinal tissue models to measure mucoadhesion of poly (methacrylate) and N-trimethylated chitosan polymers. Pharm Res 22:38-49.
266. Pontier C, Pachot J, Botham R, Lenfant B, Arnaud P. 2001. HT29-MTX and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: Role of the mucus layer. J Pharm Sci 90:1608-1619.
267. Ma TY, Hollander D, Bhalla D, Nguyen H, Krugliak P. 1992. IEC-18, a nontransformed small intestinal cell line for studying epithelial permeability. J Lab Clin Med 120:329-341.
268. Avdeef A, Tsinman O. 2006. PAMPA - a drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: In combo comparisons of HDM-, DOPC-, and DS-PAMPA models. Eur J Pharm Sci 28:43-50.
269. Takagi M, Taki Y, Sakane T, Nadai T, Sezaki H, Oku N, Yamashita S. 1998. A new interpretation of salicylic acid transport across the lipid bilayer: Implications of pH-dependent but not carrier-mediated absorption from the gastrointestinal tract. J Pharmacol Exp Ther 285:1175-1180.
270. Vrakas D, Giaginis C, Tsantili-Kakoulidou A. 2006. Different retention behavior of structurally diverse basic and neutral drugs in immobilized artificial membrane and reversed-phase high performance liquid chromatography: Comparison with octanol-water partitioning. J Chromatogr A 1116:158-164.
271. Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. 2006. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 50:2455-2463.
272. Zhang L, Zhang Z, Wu K. 2006. In vivo and real time determination of ornidazole and tinidazole and pharmacokinetic study by capillary electrophoresis with microdialysis. J Pharm Biomed Anal 41:1453-1457.
273. Amin RP, Vickers AE, Sistare F, Thompson KL, Roman RJ, Lawton M, Kramer J, Hamadeh HK, Collins J, Grissom S, Bennett L, Tucker CJ, Wild S, Kind C, Oreffo V, Davis JW 2nd, Curtiss S, Naciff JM, Cunningham M, Tennant R, Stevens J, Car B, Bertram TA, Afshari CA. 2004. Identification of putative gene based markers of renal toxicity. Environ Health Perspect 112:465-479.
274. Thompson KL, Afshari CA, Amin RP, Bertram TA, Car B, Cunningham M, Kind C, Kramer JA, Lawton M, Mirsky M, Naciff JM, Oreffo V, Pine PS, Sistare FD. 2004. Identification of platform-independent gene expression markers of cisplatin nephrotoxicity. Environ Health Perspect 112:488-494.
275. Baker VA, Harries HM, Waring JF, Duggan CM, Ni HA, Jolly RA, Yoon LW, De Souza AT, Schmid JE, Brown RH, Ulrich RG, Rockett JC. 2004. Clofibrate-induced gene expression changes in rat liver: A cross-laboratory analysis using membrane cDNA arrays. Environ Health Perspect 112:428-438.
276. Waring JF, Ulrich RG, Flint N, Morfitt D, Kalkuhl A, Staedtler F, Lawton M, Beekman JM, Suter L. 2004. Interlaboratory evaluation of rat hepatic gene expression changes induced by methapyrilene. Environ Health Perspect 112:439-448.